Summary
Whether, and how, co-occurring HIV-1 infection (HIV) and tuberculosis (TB) impact cardiovascular status, especially in adolescents with perinatally acquired HIV (APHIV), have not been examined. We hypothesized that APHIV with previous active TB have worse cardiac efficiency than APHIV without TB, which is mediated by increased inflammation. Arterial elastance (Ea) and ventricular end-systolic elastance (Ees) were assessed by cardiovascular magnetic resonance, and ventriculoarterial coupling (VAC) estimated as Ea/Ees ratio. Inflammation was measured by high sensitivity C-reactive protein (hsCRP). Previous TB in APHIV was associated with reduced cardiac efficiency, related to an altered ventriculoarterial coupling. However, we did not find evidence of hsCRP mediated effects in the association between prior TB and cardiac efficiency. The clinical significance of these findings requires further study, including a wider range of biomarkers of specific immune pathways.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Itai M. Magodoro was supported by a training award from the Fogarty International Center and National Institute of Mental Health of the National Institutes of Health (D43 TW010543) and the AIDS Healthcare Foundation, Los Angeles, USA. Heather Zar is supported by the South African Medical Research Council (SA MRC). CTAAC was funded by the NIH (R01HD074051; PI Heather Zar). Ntobeko Ntusi gratefully acknowledges funding from the National Research Foundation, South African Medical Research Council, US National Institutes of Health, Medical Research Council (UK), and the Lily and Ernst Hausmann Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee (HREC) of the Faculty of Health Sciences of the University of Cape Town (HREC 051-2013) approved all study activities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Support Itai M. Magodoro was supported by a training award from the Fogarty International Center and National Institute of Mental Health of the National Institutes of Health (D43 TW010543) and the AIDS Healthcare Foundation, Los Angeles, USA. Heather Zar is supported by the South African Medical Research Council (SA MRC). CTAAC was funded by the NIH (R01HD074051; PI Heather Zar). Ntobeko Ntusi gratefully acknowledges funding from the National Research Foundation, South African Medical Research Council, US National Institutes of Health, Medical Research Council (UK), and the Lily and Ernst Hausmann Trust.
Data Availability
All data produced in the present study are available upon reasonable request to the authors..
